[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583977":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":74,"collaborators":11,"id":76,"slug":11,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":11,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous (IV) insulin","ACTIVE_COMPARATOR",null,[13],"Other: Intravenous (IV) insulin",{"label":15,"type":16,"description":11,"interventionNames":17},"Automated insulin delivery (AID) system","EXPERIMENTAL",[18],"Device: Automated insulin delivery (AID) system",[20,24],{"type":21,"name":15,"description":22,"armGroupLabels":23,"otherNames":11},"DEVICE","An AID system incorporates data from a continuous glucose monitor (CGM) to automatically adjust the amount of insulin delivered by an insulin pump via an algorithm that incorporates multiple factors, including predicted glucose level in the next 30-60 minutes, target glucose level, and recent insulin delivery.",[15],{"type":6,"name":9,"description":25,"armGroupLabels":26,"otherNames":11},"Variable rate IV insulin infusions are used in most labor\u002Fdelivery units as the standard of care for glycemic management for pregnant people with T1D. A continuous rate of IV insulin is infused, with manual rate adjustments made based on current glucose level and hospital-specific protocols.",[9],[28],{"name":29,"affiliation":5,"role":30},"Nasim Sobhani, MD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Principal Investigator","CONTACT","(415) 307-9319","dappresearch@ucsf.edu",[38,59],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"University of California, San Diego","RECRUITING","San Diego","California","92121","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-117.16472,32.71571,{"lat":50,"lon":49},[53,57],{"name":54,"role":34,"phone":55,"phoneExt":11,"email":56},"CORI Study Team","858-249-5985","CORIstudyteam@health.ucsd.edu",{"name":58,"role":30,"phone":11,"phoneExt":11,"email":11},"Gladys (Sandy) Ramos",{"facility":5,"status":40,"city":60,"state":42,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"San Francisco","94143",{"type":47,"coordinates":63},[64,65],-122.41942,37.77493,{"lat":65,"lon":64},[68,71],{"name":69,"role":34,"phone":70,"phoneExt":11,"email":36},"Nasim Sobhani","415-307-9319",{"name":72,"role":73,"phone":11,"phoneExt":11,"email":11},"Ivonne Verduzco","SUB_INVESTIGATOR",{"type":75,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100583977",false,"NCT06883344","Automated Insulin for Management of Intrapartum Glycemia","Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial","AIMING","Inclusion Criteria:\n\n* Currently pregnant at ≥ 34 weeks\n* Known diagnosis of type 1 diabetes ≥ 1 year\n* Use of commercially available AID system since at least 28 weeks gestation\n* Singleton pregnancy\n* English- or Spanish-speaking\n\nExclusion Criteria:\n\n* Multifetal gestation\n* Planned cesarean delivery\n* Use of medications known to interfere with glucose metabolism\n* Intrauterine fetal demise\n* Physical or psychological disease likely to interfere with the conduct of the study and\u002For the ability to participate in own healthcare","FEMALE","18 Years","55 Years",{"count":87,"type":88},150,"ESTIMATED","INTERVENTIONAL",[91],"NA","The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor\u002Fdelivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are\n\n* What are the neonatal glycemic outcomes with use of AID systems during labor\u002Fdelivery?\n* Do patients report higher birth satisfaction with use of AID systems during labor\u002Fdelivery?\n* Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor\u002Fdelivery?\n\nResearchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor\u002Fdelivery) by randomly assigning participants to one or the other.",[94,95,96],"Type 1 Diabetes (T1D)","Pregnancy","Pre-Gestational Diabetes",[95,98,99,100,101],"Intrapartum glycemic management","Neonatal hypoglycemia","Perinatal care","Diabetes in pregnancy","2026-05-13",{"date":104,"type":105},"2026-05-18","ACTUAL",{"date":107,"type":105},"2025-12-05",{"date":109,"type":88},"2028-12-31",{"name":5,"class":6},2]